Cargando…

Glasgow PrognosticScore as a Predictor of BevacizumabEfficacy in the First-line Treatment with Metastatic Colorectal Cancer

Background: Inflammation might play an important role in promoting cancer growth partly by affecting tumor angiogenesis. We explored the role of Glasgow prognostic score (GPS) in metastatic colorectal cancer patients receiving first-linebevacizumab. Methods: All consecutive metastatic colorectal can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Yuanyuan, Li, Weiyu, Quan, Qi, Zhang, Bei, Yang, Qiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909943/ https://www.ncbi.nlm.nih.gov/pubmed/31839820 http://dx.doi.org/10.7150/jca.31182

Ejemplares similares

Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer
por: Yang, Qiong, et al.
Publicado: (2015)

The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer
por: Yin, Chenxi, et al.
Publicado: (2016)

Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer
por: Yang, Qiong, et al.
Publicado: (2018)

Impact of Serum Apolipoprotein A-I on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer: a Propensity Score-Matched Analysis()
por: Quan, Qi, et al.
Publicado: (2017)

The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing Chemotherapy
por: Jiang, Chang, et al.
Publicado: (2017)

The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor for head and neck cancer
por: Hanai, Nobuhiro, et al.
Publicado: (2018)

Glasgow prognostic score is a better predictor of the long-term survival in patients with gastric cancer, compared to the modified Glasgow prognostic score or high-sensitivity modified Glasgow prognostic score
por: Hirahara, Noriyuki, et al.
Publicado: (2020)

The Modified Glasgow Prognostic Score as a Predictor of Survival After Hepatectomy for Colorectal Liver Metastases
por: Nakagawa, Kazuya, et al.
Publicado: (2014)

The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation
por: Mitani, Seiichiro, et al.
Publicado: (2019)

Primary Tumor Location as a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients
por: He, Wen-Zhuo, et al.
Publicado: (2017)

Anti-epidermal or anti-vascular endothelial growth factor as first-line metastatic colorectal cancer in modified Glasgow prognostic score 2' patients
por: Dréanic, Johann, et al.
Publicado: (2015)

Inflammation-based score (Glasgow prognostic score) as an independent prognostic factor in colorectal cancer patients
por: Choi, Kyeong Woon, et al.
Publicado: (2014)

Perivascular cell coverage of intratumoral vasculature is a predictor for bevacizumab efficacy in metastatic colorectal cancer
por: Jiang, Chang, et al.
Publicado: (2018)

The application of the Glasgow prognostic score to predict the survival in patients with metastatic pancreatic carcinoma
por: Mohammed, Amrallah A., et al.
Publicado: (2022)

Validation of the conventional Glasgow Prognostic Score and development of the improved Glasgow Prognostic Score in patients with stage 0‐III colorectal cancer after curative resection
por: Ishikawa, Satoshi, et al.
Publicado: (2021)

Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer
por: Marisi, Giorgia, et al.
Publicado: (2023)

Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer
por: Passardi, Alessandro, et al.
Publicado: (2016)

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2010)

Prognostic role of Glasgow prognostic score in patients with colorectal cancer: evidence from population studies
por: Liu, Yangyang, et al.
Publicado: (2017)

Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
por: Scartozzi, M, et al.
Publicado: (2012)

Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab
por: Boisen, Mogens K., et al.
Publicado: (2014)

Glasgow Prognostic Score and modified Glasgow Prognostic Score and survival in patients with hepatocellular carcinoma: a meta-analysis
por: Lu, Lingling, et al.
Publicado: (2021)

Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer
por: Gaulin, J., et al.
Publicado: (2009)

Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2011)

Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’
por: Molina-Garrido, M J, et al.
Publicado: (2011)

Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation
por: Rossi, Luigi, et al.
Publicado: (2013)

Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials
por: Chen, Yan-xian, et al.
Publicado: (2014)

VEGF-A and ICAM-1 Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
por: Papachristos, Apostolos, et al.
Publicado: (2019)

Prognostic value of the Glasgow prognostic score in colorectal cancer: a meta-analysis of 9,839 patients
por: Lu, Xin, et al.
Publicado: (2018)

Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)
por: Jin, Ran, et al.
Publicado: (2023)

Prediction of Treatment Response and Survival with Chemotherapy for Metastatic Penile Cancer by the Modified Glasgow Prognostic Score
por: Draeger, Desiree-Louise, et al.
Publicado: (2023)

Bevacizumab in the therapy for refractory metastatic colorectal cancer
por: Mulcahy, Mary F
Publicado: (2008)

MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX
por: Kiss, I., et al.
Publicado: (2017)

Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer
por: García-Alfonso, P, et al.
Publicado: (2010)

Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial
por: Petracci, Elisabetta, et al.
Publicado: (2020)

Sarcopenia and Myosteatosis Are Associated with Neutrophil to Lymphocyte Ratio but Not Glasgow Prognostic Score in Colorectal Cancer Patients
por: Aro, Raila, et al.
Publicado: (2022)

CT texture analysis as a prognostic marker in metastatic colorectal cancer patients treated with bevacizumab
por: Chen, Shih-Hsin, et al.
Publicado: (2015)

IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2018)

The Glasgow Prognostic Score Predicts Poor Survival in Cisplatin-Based Treated Patients with Metastatic Nasopharyngeal Carcinoma
por: Chen, Cui, et al.
Publicado: (2014)

A Meta-Analysis of Glasgow Prognostic Score and Modified Glasgow Prognostic Score as Biomarkers for Predicting Survival Outcome in Renal Cell Carcinoma
por: Tong, Tongyu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hh3cuu1995su2080i0i1s5umn6